alzheimers-dementia-2018-scientifictracks

4 / 14

Page 20
December 06-07 , 2018
Amsterdam, Nether l ands
Journal of Neuropsychiatry
ISSN: 2471-8548 Alzheimer’s and Dementia 2018
1 3 t h W o r l d c o n g r e s s o n
Alzheimer’s and Dementia
During past 15 years, any new agent that was investigated in clinical trials
on Alzheimer’s disease (AD) patients has not been approved in the market.
One of the main problems in successful development of the agents for CNS
neurodegenerative disorders treatment related to multifactorial nature of
such diseases. In this relation. design of multitarget drugs was focused
that simultaneously act on several biotargets connected to pathogenesis of
neurodegenerative diseases looks as a promising strategy for developing new
generation of neuroprotective CNS agents. In the present work, we present the
results of design and synthesis of novel polypharmacophore agents superposing
in one molecule several structural pharmacophore fragments of already validated
neuroprotective agents. In particular, synthesis and study of conjugates of
phenothiazine (methylene blue) and gamma-carboline (Dimebon) derivatives, as
well as conjugates of adamantine (memantine) and carbazole derivatives was
performed. Currently several lead-compounds successfully passed preclinical
trials and ready to be moved on further clinical study.
Biography
Bachurin Sergey has completed his PhD and Dr. Sci degree
from Moscow State University, Russia. He had been
working in the University of San Francisco and in Taft’s
University (USA) in 1992 and in 1995. Since 2006, he is
serving as the Director of the Institute of Physiologically
Active Compounds, Russian Academy of Science in
Chernogolovka, Russia, and the Head of the Department of
Medicinal and Biological Chemistry. He has published more
than 220 papers in reputed journals and about 40 patents,
and has been serving as an Editorial Board Member of
repute.
Multitarget agents for the treatment of Alzheimer’s disease
Bachurin Sergey, V Sokolov, A Aksinenko V Grigoriev,
G Makhaeva and E Shevtsov
Institute of Physiologically Active Compounds, Russia
Bachurin Sergey et al., J Neurol Neurosci 2018, Volume: 2
DOI: 10.21767/2471-8548-C1-002